Healthcare company Tevogen Bio said on Monday that it plans to evaluate its proprietary antigen-specific T cell technology as the potential treatment for COVID-19 and influenza-A patients in partnership with Neal Flomenberg MD from Thomas Jefferson University.
Dr Neal Flomenberg is the chairman of Medical Oncology at Jefferson University in Philadelphia and heads the Hematologic Malignancies, Blood and Marrow Transplantation (BMT) Programme. He has developed an approach to bone-marrow transplants that assures that the majority of blood and bone-marrow cancer patients can benefit from this potentially curative treatment.
Through the collaboration, Tevogen will leverage its proprietary immunotherapy platform with Dr Flomenberg's expertise and research prowess to investigate potential treatments for viral infections. Tevogen CEO Ryan Saadi, MD, MPH, is leading the new biotech's efforts.
This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr Flomenberg's expertise in immunology, histocompatibility and pioneering work in the immunology of stem cell transplantation.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories